Breaking News, Financial News

Amgen 4Q Results

Ten products deliver double-digit sales growth in the quarter, including Repatha, up 45% to $606 million.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Amgen

Amgen 4Q Revenues: $9.1 billion (+11%) 4Q Earnings: $627 million (-18%) FY Revenues: $33.4 billion (+19%) FY Earnings: $4.1 billion (-39%) Comments: Product sales grew 11%, primarily driven by 14% volume growth. Excluding sales from the Horizon Therapeutics acquisition, product sales grew 10%. Ten products delivered double-digit sales growth in the quarter, including Repatha, up 45% to $606 million, BLINCYTO, up 58% to $381 million, TEZSPIRE, up 67% to $296 million, EVENITY, up...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters